Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma

A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)

Trial Details

NCT ID
NCT06755450
Phase
PHASE1
Sponsor
Aurigene Discovery Technologies Limited
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • AUR112
Locations (sample)
  • Vadodara, Gujarat, India|22.29941,73.20812
  • Jhajjar, Haryana, India|28.6063,76.6565
  • Bangalore, Karnataka, India|12.97194,77.59369
  • Bangalore, Karnataka, India|12.97194,77.59369
  • Chhatrapati Sambhajinagar, Maharashtra, India|19.87757,75.34226

Key Eligibility Criteria

  • Males and females ≥ 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1
  • Acceptable bone marrow and organ function at screening as described below:
  • ANC ≥ 1000/μL (without WBC growth factor support)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →